{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:06:01Z","timestamp":1793397961072,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd014965","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000}}],"reference-count":158,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014965.pub2","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T07:07:20Z","timestamp":1747811240000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Atypical antipsychotics for autism spectrum disorder: a network meta-analysis"],"prefix":"10.1002","volume":"2025","author":[{"given":"Nicol\u00e1s","family":"Meza","sequence":"additional","affiliation":[{"name":"Interdisciplinary Centre for Health Studies CIESAL; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan VA","family":"Franco","sequence":"additional","affiliation":[{"name":"Institute of General Practice; Medical Faculty of the Heinrich-Heine-University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Sguassero","sequence":"additional","affiliation":[{"name":"Cochrane Response; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Interdisciplinary Centre for Health Studies CIESAL; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Micaela","family":"Escobar Liquitay","sequence":"additional","affiliation":[{"name":"Research Department; Instituto Universitario Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald","family":"Rees","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, School of Medicine; Universidad de Valpara\u00edso; Valpara\u00edso Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Rojas","sequence":"additional","affiliation":[{"name":"Department of Child Neurology, School of Medicine; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Rojas","sequence":"additional","affiliation":[{"name":"Interdisciplinary Centre for Health Studies CIESAL; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pringsheim","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences; University of Calgary; Calgary, Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Madrid","sequence":"additional","affiliation":[{"name":"Interdisciplinary Centre for Health Studies CIESAL; Universidad de Valpara\u00edso; Vi\u00f1a del Mar Chile"},{"name":"Iberoamerican Cochrane Centre; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"10.1002\/14651858.CD014965.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"104202","DOI":"10.1016\/j.ridd.2022.104202","article-title":"Estimation of the minimal clinically important difference on the Aberrant Behaviour Checklist-Irritability (ABC-I) for people with intellectual disabilities who display aggressive challenging behaviour: a triangulated approach","volume":"124","author":"Hassiotis","year":"2022","journal-title":"Research in Developmental Disabilities"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0002|cit2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0003|cit3","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0004|cit4","unstructured":"World Health Organization ICD-11: International Classification of Diseases, 11th Revision icd.who.int\/en"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/13623613221130845","article-title":"Preferences for identity-first versus person-first language in a US sample of autism stakeholders","volume":"27","author":"Taboas","year":"2023","journal-title":"Autism"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/13623613221117914","article-title":"'Autistic person' or 'person with autism'? Person-first language preference in Dutch adults with autism and parents","volume":"27","author":"Buijsman","year":"2023","journal-title":"Autism"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10803-020-04425-3","article-title":"\"it defines who I am\" or \"it's something I have\": what language do [autistic] Australian adults [on the autism spectrum] prefer?","volume":"53","author":"Bury","year":"2023","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cpr.2013.11.002","article-title":"Cognitive, language, social and behavioural outcomes in adults with autism spectrum disorders: a systematic review of longitudinal follow-up studies in adulthood","volume":"34","author":"Magiati","year":"2014","journal-title":"Clinical Psychology Review"},{"issue":"8","key":"10.1002\/14651858.CD014965.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s10803-006-0147-5","article-title":"Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification","volume":"36","author":"Lecavalier","year":"2006","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"23","key":"10.1002\/14651858.CD014965.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.21037\/atm.2019.11.53","article-title":"Emerging biomarkers in autism spectrum disorder: a systematic review","volume":"7","author":"Frye","year":"2019","journal-title":"Annals of Translational Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41398-020-01178-6","article-title":"Emerging behavioral and neuroimaging biomarkers for early and accurate characterization of autism spectrum disorders: a systematic review","volume":"11","author":"Hiremath","year":"2021","journal-title":"Translational Psychiatry"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-publhealth-031816-044318","article-title":"The changing epidemiology of autism spectrum disorders","volume":"38","author":"Lyall","year":"2017","journal-title":"Annual Review of Public Health"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/aur.2696","article-title":"Global prevalence of autism: a systematic review update","volume":"15","author":"Zeidan","year":"2022","journal-title":"Autism Research"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"110326","DOI":"10.1016\/j.pnpbp.2021.110326","article-title":"The pediatric psychopharmacology of autism spectrum disorder: a systematic review \u2013 part I: the past and the present","volume":"110","author":"Persico","year":"2021","journal-title":"Progress in Neuropsychopharmacolgy & Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7202a1","article-title":"Prevalence and characteristics of autism spectrum disorder among children aged 8 years \u2013 autism and developmental disabilities monitoring network, 11 sites, United States, 2020","volume":"72","author":"Maenner","year":"2023","journal-title":"MMWR. Surveillance Summaries: Morbidity and Mortality Weekly Report"},{"issue":"12","key":"10.1002\/14651858.CD014965.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1007\/s10803-020-04494-4","article-title":"National and state estimates of adults with autism spectrum disorder","volume":"50","author":"Dietz","year":"2020","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1017\/S2045796018000483","article-title":"Prevalence of autism spectrum disorder in a large Italian catchment area: a school-based population study within the ASDEU project","volume":"29","author":"Narzisi","year":"2018","journal-title":"Epidemiology and Psychiatric Sciences"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/archgenpsychiatry.2011.38","article-title":"Epidemiology of autism spectrum disorders in adults in the community in England","volume":"68","author":"Brugha","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.rasd.2019.03.002","article-title":"The influence of age and ASD on verbal fluency networks","volume":"63","author":"Baxter","year":"2019","journal-title":"Research in Autism Spectrum Disorders"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/hbm.23345","article-title":"Age-related differences in autism: the case of white matter microstructure","volume":"38","author":"Koolschijn","year":"2017","journal-title":"Human Brain Mapping"},{"issue":"10","key":"10.1002\/14651858.CD014965.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1007\/s10803-017-3238-6","article-title":"Patterns of age-related cognitive differences in adults with autism spectrum disorder","volume":"47","author":"Powell","year":"2017","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.rasd.2019.02.008","article-title":"Age group differences in executive network functional connectivity and relationships with social behavior in men with autism spectrum disorder","volume":"63","author":"Walsh","year":"2019","journal-title":"Research in Autism Spectrum Disorders"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/HRP.0000000000000282","article-title":"Treatment of aggression in adults with autism spectrum disorder: a review","volume":"29","author":"Im","year":"2021","journal-title":"Harvard Review of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD014965.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.rasd.2014.03.021","article-title":"Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: a systematic review","volume":"8","author":"Sawyer","year":"2014","journal-title":"Research in Autism Spectrum Disorders"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0025|cit25","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: a review","volume":"40","author":"LeClerc","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Meza N Rojas V Escobar Liquitay CM P\u00e9rez I \u00a0Aguilera Johnson F \u00a0Amarales Osorio C Non-pharmacological interventions for autism spectrum disorder in children: an overview of systematic reviews BMJ Evidence-Based Medicine 2022 28 4 273 82 10.1136\/bmjebm-2021-111811 35217568","DOI":"10.1136\/bmjebm-2021-111811"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1542\/peds.2007-2362","article-title":"Management of children with autism spectrum disorders","volume":"120","author":"Myers","year":"2007","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0028|cit28","unstructured":"Approval package for ABILIFY; November 2009 Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/021436Orig1s027.pdf"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0029|cit29","unstructured":"Approval package for risperdal; June 2005 Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21346_RisperdalTOC.cfm"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Fieiras C Chen MH Escobar Liquitay CM Meza N Rojas V Franco JV Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews BMJ Evidence-Based Medicine 2023 28 1 7 14 10.1136\/bmjebm-2021-111804 35101925","DOI":"10.1136\/bmjebm-2021-111804"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0031|cit31","volume-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"Brunton","year":"2022"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Safety"},{"issue":"7","key":"10.1002\/14651858.CD014965.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1517\/14656566.2016.1154536","article-title":"Psychopharmacological interventions in autism spectrum disorder","volume":"17","author":"Accordino","year":"2016","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/cap.2018.0115","article-title":"Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis","volume":"29","author":"Fallah","year":"2019","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatry and Human Development"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/phar.2271","article-title":"Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial","volume":"39","author":"DeVane","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s12888-020-02956-8","article-title":"Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review","volume":"20","author":"D'Al\u00f2","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41583-022-00576-7","article-title":"Genomics, convergent neuroscience and progress in understanding autism spectrum disorder","volume":"23","author":"Willsey","year":"2022","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","article-title":"Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences","volume":"192","author":"Aringhieri","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? : a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD014965.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1517\/14656566.3.12.1773","article-title":"Aripiprazole: profile on efficacy and safety","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12955-021-01669-0","article-title":"Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis","volume":"19","author":"D'Al\u00f2","year":"2021","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0044|cit44","volume-title":"First and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update","author":"Pillay","year":"2017"},{"issue":"10","key":"10.1002\/14651858.CD014965.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011769.pub2","article-title":"Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)","author":"Iffland","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0046|cit46","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014965","article-title":"Atypical antipsychotics for autism spectrum disorder: a network meta-analysis","author":"Meza","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jrsm.1599","article-title":"Identifying and managing problematic trials: a research integrity assessment tool for randomized controlled trials in evidence synthesis","volume":"14","author":"Weibel","year":"2023","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0050|cit50","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0051|cit51","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0052|cit52","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision","author":"World Health Organization","year":"2011"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/BF02172145","article-title":"Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders","volume":"24","author":"Lord","year":"1994","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1023\/A:1005592401947","article-title":"The Autism Diagnostic Observation Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism","volume":"30","author":"Lord","year":"2000","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0056|cit56","volume-title":"Aberrant Behavior Checklist: Manual","author":"Aman","year":"1986"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1176\/ajp.143.1.35","article-title":"The Overt Aggression Scale for the objective rating of verbal and physical aggression","volume":"143","author":"Yudofsky","year":"1986","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1023\/a:1013299028321","article-title":"The Behavior Problems Inventory: an instrument for the assessment of self-injury, stereotyped behavior, and aggression\/destruction in individuals with developmental disabilities","volume":"31","author":"Rojahn","year":"2001","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0059|cit59","first-page":"257","article-title":"Critical analysis of the disability in Parkinson's disease","volume":"5","author":"Webster","year":"1968","journal-title":"Modern Treatment"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0060|cit60","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"issue":"2-3","key":"10.1002\/14651858.CD014965.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD014965.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0064|cit64","volume-title":"Vineland Screener: Overview, Reliability, Validity, Administration, and Scoring","author":"Sparrow","year":"1993"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Shokraneh F Adams CE Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis Health Information and Libraries Journal 2023 40 2 201 6 10.1111\/hir.12366 33615663","DOI":"10.1111\/hir.12366"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0066|cit66","unstructured":"Covidence Veritas Health Innovation 2021"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0067|cit67","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0068|cit68","unstructured":"Higgins JP \u00a0Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0070|cit70","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0071|cit71","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"10","key":"10.1002\/14651858.CD014965.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLOS One"},{"issue":"23","key":"10.1002\/14651858.CD014965.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/sim.4001","article-title":"Evaluating novel agent effects in multiple-treatments meta-regression","volume":"29","author":"Salanti","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","article-title":"The Rank-Heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes","volume":"76","author":"Veroniki","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"24","key":"10.1002\/14651858.CD014965.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Statistical Methods in Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"171","author":"Higgins","year":"2009","journal-title":"Journal of the Royal Statistical Society. Series A: Statistics in Society"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"White IR Network meta-analysis Stata Journal: Promoting Communications on Statistics and Stata 2015 15 4 951 85 10.1177\/1536867X1501500403","DOI":"10.1177\/1536867X1501500403"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0081|cit81","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","article-title":"Conceptual and technical challenges in network meta-analysis","volume":"159","author":"Cipriani","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Medicine"},{"issue":"7","key":"10.1002\/14651858.CD014965.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Caldwell DM Ades AE Higgins JP Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 2005 331 7521 897 900 10.1136\/bmj.331.7521.897 16223826","DOI":"10.1136\/bmj.331.7521.897"},{"issue":"20","key":"10.1002\/14651858.CD014965.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1471-2288-12-138","article-title":"Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons","volume":"12","author":"Song","year":"2012","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2288-14-106","article-title":"Characteristics of a loop of evidence that affect detection and estimation of inconsistency: a simulation study","volume":"14","author":"Veroniki","year":"2014","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0090|cit90","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0091|cit91","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0093|cit93","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0094|cit94","unstructured":"CINeMA: Confidence in Network Meta-Analysis Institute of Social and Preventive Medicine, University of Bern 2017"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0096|cit96","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0097|cit97","unstructured":"Evaluating the effectiveness of aripiprazole and D-cycloserine to treat symptoms associated with autism https:\/\/clinicaltrials.gov\/study\/NCT00198107"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0098|cit98","unstructured":"Efficacy of aripiprazole versus placebo in the reduction of aggressive and aberrant behavior in autistic children https:\/\/clinicaltrials.gov\/study\/NCT00468130"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0099|cit99","unstructured":"Study of aripiprazole in the treatment of pervasive developmental disorders https:\/\/clinicaltrials.gov\/study\/NCT00870727"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0100|cit100","unstructured":"A study to evaluate the efficacy and safety of risperidone (R064766) in children and adolescents with irritability associated with autistic disorder https:\/\/clinicaltrials.gov\/study\/NCT01624675"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhood\/adolescent pervasive developmental disorder","volume":"16","author":"Hollander","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD014965.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders","volume":"55","author":"McDougle","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD014965.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40272-016-0183-3","article-title":"Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD: a pilot, open-label, randomized controlled study","volume":"18","author":"Lamberti","year":"2016","journal-title":"Paediatric Drugs"},{"issue":"16","key":"10.1002\/14651858.CD014965.pub2-BIB0104|cit104","first-page":"1893","article-title":"Efficacy and safety of paliperidone and aripiprazole in the treatment of autism","volume":"25","author":"Ma","year":"2016","journal-title":"Chinese Journal of New Drugs"},{"issue":"4","key":"10.1002\/14651858.CD014965.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"501","DOI":"10.32598\/bcn.2021.3122.1","article-title":"Therapeutic impacts of hyperbaric oxygen therapy and risperidone on children with autism: a clinical trial","volume":"14","author":"Mohamed","year":"2023","journal-title":"Basic and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0106|cit106","unstructured":"A controlled study of olanzapine in children with autism https:\/\/clinicaltrials.gov\/study\/NCT00057408"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0107|cit107","unstructured":"Risperidone treatment in children with autism spectrum disorder and high levels of repetitive behavior https:\/\/www.clinicaltrials.gov\/study\/NCT01171937"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0108|cit108","unstructured":"Aripiprazole oral solution in the treatment of children and adolescents with autistic disorder https:\/\/clinicaltrials.gov\/study\/NCT03487770"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0109|cit109","unstructured":"Study of cariprazine oral capsules or solution to assess adverse events and change in irritability due to autism spectrum disorder (ASD) in participants aged 5-17 years with ASD. 2022 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05439616"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0110|cit110","unstructured":"Antipsychotic drug for autism https:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=47732&EncHid=&userName=CTRI\/2021\/12\/038721."},{"key":"10.1002\/14651858.CD014965.pub2-BIB0111|cit111","unstructured":"A randomized, double-blind, placebo-controlled maintenance of effect study of olanzapine in the treatment of disruptive behavioral symptoms in children and adolescents with pervasive developmental disorders - HGMR https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-005346-37\/NL."},{"key":"10.1002\/14651858.CD014965.pub2-BIB0112|cit112","unstructured":"Pragmatic trial comparing weight gain in children with autism taking risperidone versus aripiprazole https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04903353."},{"key":"10.1002\/14651858.CD014965.pub2-BIB0113|cit113","unstructured":"EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: a RANDOMIZED CONTROLLED TRIAL (versus) https:\/\/clinicaltrials.gov\/study\/NCT05868720."},{"key":"10.1002\/14651858.CD014965.pub2-BIB0114|cit114","unstructured":"Pimavanserin for rigid-compulsive symptoms in autism spectrum disorder https:\/\/clinicaltrials.gov\/study\/NCT05999240."},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0116|cit116","first-page":"S110","article-title":"Efficacy and safety of flexibly-dosed aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents (6\u201317 years)","volume":"66","author":"Lewis","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0117|cit117","unstructured":"Study of aripiprazole in the treatment of serious behavioral problems in children and adolescents with autistic disorder (AD) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-005111-40\/results"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0118|cit118","unstructured":"Study of aripiprazole in the treatment of children and adolescents with autistic disorder (AD) https:\/\/clinicaltrials.gov\/study\/NCT00337571"},{"issue":"11","key":"10.1002\/14651858.CD014965.pub2-BIB0119|cit119","first-page":"1110","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","article-title":"Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Pandina","year":"2007","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/S0924-977X(04)80324-9","article-title":"Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo controlled trial","volume":"14","author":"Light","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0123|cit123","first-page":"S275","article-title":"Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): a randomized, double-blind, placebo-controlled trial","volume":"7","author":"Light","year":"2004","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0124|cit124","first-page":"S88","article-title":"Risperidone improves symptoms in children with autism","volume":"58","author":"Pandina","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0125|cit125","unstructured":"A study of the effectiveness and safety of risperidone versus placebo in the treatment of children with autistic disorder and other pervasive developmental disorders (PDD) https:\/\/clinicaltrials.gov\/study\/NCT00261508"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014965.pub2-BIB0126|cit126","first-page":"S631","article-title":"Symptomatic improvement demonstrated in children with autism treated with risperidone","volume":"15","author":"Pandina","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/phar.2271","article-title":"Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial","volume":"39","author":"DeVane","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatry and Human Development"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0129|cit129","unstructured":"Aripiprazole versus risperidone for treatment of autism https:\/\/irct.behdasht.gov.ir\/trial\/4094"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s10578-016-0704-x","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study","volume":"48","author":"Ichikawa","year":"2017","journal-title":"Child Psychiatry and Human Development"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0131|cit131","unstructured":"A short treatment study of aripiprazole in pediatric patients with autistic disorder https:\/\/clinicaltrials.gov\/study\/NCT01617447"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0132|cit132","unstructured":"A short treatment study of aripiprazole in pediatric patients with autistic disorder https:\/\/jrct.niph.go.jp\/latest-detail\/jRCT2080221819"},{"issue":"8","key":"10.1002\/14651858.CD014965.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0134|cit134","unstructured":"A study of the effectiveness and safety of two doses of risperidone in the treatment of children and adolescents with autistic disorder https:\/\/clinicaltrials.gov\/study\/NCT00576732"},{"issue":"4","key":"10.1002\/14651858.CD014965.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","article-title":"Lurasidone for the treatment of irritability associated with autistic disorder","volume":"46","author":"Loebel","year":"2016","journal-title":"Journal of Autism and Developmental Disorders"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0136|cit136","unstructured":"Lurasidone pediatric autism study https:\/\/clinicaltrials.gov\/study\/NCT01911442."},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eurpsy.2015.11.004","article-title":"Initial severity and efficacy of risperidone in autism: results from the RUPP trial","volume":"32","author":"Levine","year":"2016","journal-title":"European Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1362361315574889","article-title":"Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: results from two multi-site trials","volume":"20","author":"Scahill","year":"2016","journal-title":"Autism"},{"issue":"10","key":"10.1002\/14651858.CD014965.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1089\/cap.2016.0090","article-title":"No apparent cardiac conduction effects of acute treatment with risperidone in children with autism spectrum disorder","volume":"26","author":"Vo","year":"2016","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD014965.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/cap.2009.0022","article-title":"Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability","volume":"20","author":"Arnold","year":"2010","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/ebm.8.1.22","article-title":"Risperidone was safe and effective for short term treatment of children with autism and serious behavioural disturbances","volume":"8","author":"McCracken","year":"2003","journal-title":"Evidence-based Medicine"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0144|cit144","unstructured":"Treatment of autism in children and adolescents https:\/\/clinicaltrials.gov\/study\/NCT00005014"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD014965.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/cap.2007.0133","article-title":"Cognitive effects of risperidone in children with autism and irritable behavior","volume":"18","author":"Aman","year":"2008","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD014965.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD014965.pub2-BIB0149|cit149","first-page":"1443","article-title":"Parent-defined target symptoms respond to risperidone in RUPP Autism study: customer approach to clinical trials","volume":"42","author":"Arnold","year":"2003","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1038\/tp.2013.26","article-title":"Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP Autism Network Risperidone Studies","volume":"3","author":"Nurmi","year":"2013","journal-title":"Translational Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD014965.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"Journal of Child Neurology"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0153|cit153","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009043.pub3","article-title":"Aripiprazole for autism spectrum disorders (ASD)","author":"Hirsch","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0154|cit154","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005040.pub2","article-title":"Risperidone for autism spectrum disorder","author":"Jesner","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD014965.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00787-020-01587-4","article-title":"ESCAP practice guidance for autism: a summary of evidence-based recommendations for diagnosis and treatment","volume":"30","author":"Fuentes","year":"2021","journal-title":"European Child & Adolescent Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD014965.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaac.2013.10.013","article-title":"Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder","volume":"53","author":"Volkmar","year":"2014","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD014965.pub2-BIB0157|cit157","unstructured":"National Institute for Health and Care Excellence Autism spectrum disorder in adults: diagnosis and management https:\/\/www.nice.org.uk\/guidance\/cg142"},{"issue":"1","key":"10.1002\/14651858.CD014965.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/acps.12644","article-title":"Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review","volume":"135","author":"Jobski","year":"2017","journal-title":"Acta Psychiatrica Scandinavica"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:08:46Z","timestamp":1784815726000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014965.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":158,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014965.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}